Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

ASH 2015

5 - 7 Dec 2015
TBC, Orlando, United States of America
Videos
News
ASH 2015: Latest in CLL
Prof John Gribben, Prof Stephan Stilgenbauer, Dr Alessandra Tedeschi, Dr...
ASH 2015: Latest in CLL ( Prof John Gribben, Prof Stephan Stilgenbauer, Dr Alessandra Tedeschi, Dr Patrick Thornton )
7 Dec 2015
Long-term outcomes after blinatumomab treatment for ALL
Dr Nicola Gökbuget - University of Frankfurt, Frankfurt, Germany
Long-term outcomes after blinatumomab treatment for ALL ( Dr Nicola Gökbuget - University of Frankfurt, Frankfurt, Germany )
7 Dec 2015
ASH 2015: Highlights
ecancertv
ASH 2015: Highlights ( ecancertv )
7 Dec 2015
How is cancer-related venous thromboembolism treated in real world practice?
Prof Alok Khorana - Cleveland Clinic, Cleveland, USA
How is cancer-related venous thromboembolism treated in real world practice? ( Prof Alok Khorana - Cleveland Clinic, Cleveland, USA )
7 Dec 2015
Dalteparin thromboprophylaxis for cancer patients at high risk of venous...
Prof Alok Khorana - Cleveland Clinic, Cleveland, USA
Dalteparin thromboprophylaxis for cancer patients at high risk of venous thromboembolism ( Prof Alok Khorana - Cleveland Clinic, Cleveland, USA )
7 Dec 2015
Response to rituximab induction is a predictive biomarker in post-transplant...
Prof Corrado Tarella - Istituto Europeo di Oncologia, Milano, Italy
Response to rituximab induction is a predictive biomarker in post-transplant lymphoproliferative disorder ( Prof Corrado Tarella - Istituto Europeo di Oncologia, Milano, Italy )
7 Dec 2015
“Low but real” risk of myelodysplastic syndromes caused by thyroid cancer...
Dr Sudipto Mukherjee - Cleveland Clinic, Cleveland, USA
“Low but real” risk of myelodysplastic syndromes caused by thyroid cancer treatment ( Dr Sudipto Mukherjee - Cleveland Clinic, Cleveland, USA )
7 Dec 2015
High dose chemotherapy plus transplant remains standard care for young newly...
Dr Francesca Gay - University of Torino, Torino, Italy
High dose chemotherapy plus transplant remains standard care for young newly diagnosed multiple myeloma patients ( Dr Francesca Gay - University of Torino, Torino, Italy )
7 Dec 2015
ENDEAVOR: carfilzomib new standard in multiple myeloma?
Dr Keith Stewart - Mayo Clinic, Rochester, USA
ENDEAVOR: carfilzomib new standard in multiple myeloma? ( Dr Keith Stewart - Mayo Clinic, Rochester, USA )
7 Dec 2015
How can functional drug screening guide personalised cancer therapy?
Prof Jeff Tyner - Oregon Health & Science University, Portland, USA
How can functional drug screening guide personalised cancer therapy? ( Prof Jeff Tyner - Oregon Health & Science University, Portland, USA )
7 Dec 2015
How do genes influence the development of chronic idiopathic thrombocytopenic...
Prof Jenny Despotovic - Texas Children's Cancer Center, Houston, USA
How do genes influence the development of chronic idiopathic thrombocytopenic purpura? ( Prof Jenny Despotovic - Texas Children's Cancer Center, Houston, USA )
7 Dec 2015
Combining treatment options for higher risk myelodysplastic syndromes and...
Dr Mikkael Sekeres - Cleveland Clinic Foundation, Cleveland, USA
Combining treatment options for higher risk myelodysplastic syndromes and chronic myelomonocytic leukaemia ( Dr Mikkael Sekeres - Cleveland Clinic Foundation, Cleveland, USA )
7 Dec 2015
ASH 2015: Highlights in mantle cell lymphoma
Prof Simon Rule and Prof Steven Le Gouill
ASH 2015: Highlights in mantle cell lymphoma ( Prof Simon Rule and Prof Steven Le Gouill )
7 Dec 2015
Incidence of and predictors for early death in paediatric patients with acute...
Dr Oussama Abla - The Hospital for Sick Children, Toronto, Canada
Incidence of and predictors for early death in paediatric patients with acute promyelocytic leukaemia ( Dr Oussama Abla - The Hospital for Sick Children, Toronto, Canada )
6 Dec 2015
Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic...
Prof Giovanni Martinelli - University of Bologna, Bologna, Italy
Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic leukaemia subtype ( Prof Giovanni Martinelli - University of Bologna, Bologna, Italy )
6 Dec 2015
Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia
Dr Sébastien Maury - Hôpital Henri Mondor, Créteil, France
Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia ( Dr Sébastien Maury - Hôpital Henri Mondor, Créteil, France )
6 Dec 2015
First all-oral treatment for relapsed and treatment-resistant multiple myeloma
Prof Philippe Moreau - University of Nantes, Nantes, France
First all-oral treatment for relapsed and treatment-resistant multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )
6 Dec 2015
Experimental oral therapy for high-risk CLL shows promise
Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany
Experimental oral therapy for high-risk CLL shows promise ( Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany )
6 Dec 2015
Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia
Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano...
Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia ( Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy )
6 Dec 2015
Idelalisib combination therapy in relapsed or treatment-resistant CLL better...
Dr Andrew Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA
Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimen ( Dr Andrew Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA )
6 Dec 2015
ASH 2015: Novel combination approaches for multiple myeloma
Prof Marivi Mateos, Prof Sagar Lonial, Dr Torben Plesner, Prof Meletios...
ASH 2015: Novel combination approaches for multiple myeloma ( Prof Marivi Mateos, Prof Sagar Lonial, Dr Torben Plesner, Prof Meletios Dimopoulos )
6 Dec 2015
ASH 2015: Ibrutinib as first-line treatment for chronic lymphocytic leukaemia
Prof John Gribben and Prof Stilgenbauer
ASH 2015: Ibrutinib as first-line treatment for chronic lymphocytic leukaemia ( Prof John Gribben and Prof Stilgenbauer )
6 Dec 2015
ASH 2015: New targeted therapies for haematological malignancies
Dr Robert Hromas - University of Florida, Gainesville, USA
ASH 2015: New targeted therapies for haematological malignancies ( Dr Robert Hromas - University of Florida, Gainesville, USA )
6 Dec 2015
Using epigenetics to manipulate cancer cells
Dr Stephen Nimer - Sylvester Comprehensive Cancer, Miami, USA
Using epigenetics to manipulate cancer cells ( Dr Stephen Nimer - Sylvester Comprehensive Cancer, Miami, USA )
6 Dec 2015
Overcoming the barriers of the P53 dysfunction to cure blood cancers
Dr Guillermina Lozano - MD Anderson Cancer Center, Houston, USA
Overcoming the barriers of the P53 dysfunction to cure blood cancers ( Dr Guillermina Lozano - MD Anderson Cancer Center, Houston, USA )
6 Dec 2015
Exciting new immunosuppressive therapy treatment for aplastic anaemia
Dr Danielle Townsley - George Washington University School of Medicine...
Exciting new immunosuppressive therapy treatment for aplastic anaemia ( Dr Danielle Townsley - George Washington University School of Medicine, Washington, USA )
6 Dec 2015
Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia...
Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany
Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise ( Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany )
6 Dec 2015
Combination therapy with idelalisib better prevents disease progression in...
Dr Andrew D. Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA
Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen ( Dr Andrew D. Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA )
6 Dec 2015
Study underscores promise of targeted therapies as first-line approach for...
Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano...
Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia ( Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy )
6 Dec 2015
First targeted therapy for multiple myeloma effective against hard-to-treat...
Dr Torben Plesner - Vejle Hospital, University of Southern Denmark, Vejle...
First targeted therapy for multiple myeloma effective against hard-to-treat disease ( Dr Torben Plesner - Vejle Hospital, University of Southern Denmark, Vejle, Denmark )
6 Dec 2015
First targeted therapy for genetically defined subset of patients with acute...
Dr Richard M. Stone - Dana-Farber Cancer Institute, Boston, USA
First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia significantly improves survival ( Dr Richard M. Stone - Dana-Farber Cancer Institute, Boston, USA )
6 Dec 2015
Exciting evidence for first all-oral treatment for relapsed and treatment...
Prof Philippe Moreau - University of Nantes, Nantes, France
Exciting evidence for first all-oral treatment for relapsed and treatment-resistant multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )
6 Dec 2015
Study finds new use for rituximab in acute lymphoblastic leukaemia
Prof Sébastien Maury - Hôpital Henri Mondor, Créteil, France
Study finds new use for rituximab in acute lymphoblastic leukaemia ( Prof Sébastien Maury - Hôpital Henri Mondor, Créteil, France )
6 Dec 2015
First targeted therapy for multiple myeloma effective against hard-to-treat...
Dr Torben Plesner - Vejle Hospital, Vejle, Denmark
First targeted therapy for multiple myeloma effective against hard-to-treat disease ( Dr Torben Plesner - Vejle Hospital, Vejle, Denmark )
6 Dec 2015
First targeted therapy for genetically defined subset with acute myeloid...
Dr Richard Stone - Dana Farber Cancer Institute, Boston, USA
First targeted therapy for genetically defined subset with acute myeloid leukaemia significantly improves survival ( Dr Richard Stone - Dana Farber Cancer Institute, Boston, USA )
6 Dec 2015
Variants for increased risk of osteonecrosis in paediatric acute lymphocytic...
Dr Seth Karol - St Jude Children's Research Hospital, Tampa, USA
Variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified ( Dr Seth Karol - St Jude Children's Research Hospital, Tampa, USA )
6 Dec 2015
Immunotherapy makes patients’ tumours "melt away"
Dr Joshua Brody - Mount Sinai Medical Center, New York, USA
Immunotherapy makes patients’ tumours "melt away" ( Dr Joshua Brody - Mount Sinai Medical Center, New York, USA )
6 Dec 2015
Quality assessment looking at rivaroxaban for cancer-related thrombosis
Dr Gerald Soff - Memorial Sloan Kettering Cancer Center, New York, USA
Quality assessment looking at rivaroxaban for cancer-related thrombosis ( Dr Gerald Soff - Memorial Sloan Kettering Cancer Center, New York, USA )
6 Dec 2015
Guidance for anticoagulation management in the setting of thrombocytopenia in...
Dr Gerald Soff - Memorial Sloan Kettering Cancer Center, New York, USA
Guidance for anticoagulation management in the setting of thrombocytopenia in cancer patients ( Dr Gerald Soff - Memorial Sloan Kettering Cancer Center, New York, USA )
6 Dec 2015
Genetic variant that signifies higher risk for avascular necrosis in children...
Dr Peter D. Cole - Albert Einstein College of Medicine, New York, USA
Genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia ( Dr Peter D. Cole - Albert Einstein College of Medicine, New York, USA )
6 Dec 2015
Tosedostat for elderly acute myeloid leukaemia
Dr Giuseppe Visani - Ospedale S. Salvatore, Pesaro, Italy
Tosedostat for elderly acute myeloid leukaemia ( Dr Giuseppe Visani - Ospedale S. Salvatore, Pesaro, Italy )
5 Dec 2015
ASH 2015: Monoclonal antibodies for multiple myeloma
Dr Saad Usmani and Prof Thierry Facon
ASH 2015: Monoclonal antibodies for multiple myeloma ( Dr Saad Usmani and Prof Thierry Facon )
5 Dec 2015
Anti-Bcl2 therapy shows promise for relapsed/refractory multiple myeloma
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
Anti-Bcl2 therapy shows promise for relapsed/refractory multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
5 Dec 2015
Daratumumab for multiple myeloma
Prof Sagar Lonial - Emory University School of Medicine, Atlanta, USA
Daratumumab for multiple myeloma ( Prof Sagar Lonial - Emory University School of Medicine, Atlanta, USA )
5 Dec 2015
Children most at risk of over-reporting adherence to at-home chemotherapy...
Dr Wendy Landier - University of Alabama at Birmingham, Birmingham, USA
Children most at risk of over-reporting adherence to at-home chemotherapy regimen ( Dr Wendy Landier - University of Alabama at Birmingham, Birmingham, USA )
5 Dec 2015
Cancer-associated thrombosis: Switching patients to warfarin after 6-month...
Dr Chatree Chai-Adisaksopha - McMaster University, Hamilton, Canada
Cancer-associated thrombosis: Switching patients to warfarin after 6-month completion of anticoagulant treatment ( Dr Chatree Chai-Adisaksopha - McMaster University, Hamilton, Canada )
5 Dec 2015
Study suggests warfarin is acceptable for long-term treatment of cancer...
Dr Chatree Chai-Adisaksopha - McMaster University, Hamilton, Canada
Study suggests warfarin is acceptable for long-term treatment of cancer-associated thrombosis ( Dr Chatree Chai-Adisaksopha - McMaster University, Hamilton, Canada )
5 Dec 2015
Researchers identify children most at risk of over-reporting adherence to at...
Dr Wendy Landier - University of Alabama at Birmingham, Birmingham, USA
Researchers identify children most at risk of over-reporting adherence to at-home chemotherapy regimen ( Dr Wendy Landier - University of Alabama at Birmingham, Birmingham, USA )
5 Dec 2015
Research provides guidance for anticoagulation management in the setting of...
Dr Gerald A. Soff - Memorial Sloan Kettering Cancer Center, New York, USA
Research provides guidance for anticoagulation management in the setting of thrombocytopenia in cancer patients ( Dr Gerald A. Soff - Memorial Sloan Kettering Cancer Center, New York, USA )
5 Dec 2015
Promising new strategy for treating children with acute lymphocytic leukaemia
Dr Elizabeth Raetz - University of Utah, Salt Lake City, USA
Promising new strategy for treating children with acute lymphocytic leukaemia ( Dr Elizabeth Raetz - University of Utah, Salt Lake City, USA )
5 Dec 2015
Comment: Whole exome sequencing finds genes associated with autoimmune platelet...
Dr Wendy Stock - University of Chicago, Chicago, USA
Comment: Whole exome sequencing finds genes associated with autoimmune platelet disorder in children ( Dr Wendy Stock - University of Chicago, Chicago, USA )
5 Dec 2015
Comment: Classification system based on cytogenetics and treatment response...
Dr Wendy Stock - University of Chicago, Chicago, USA
Comment: Classification system based on cytogenetics and treatment response identifies leukaemia patients with high-risk clinical features ( Dr Wendy Stock - University of Chicago, Chicago, USA )
5 Dec 2015
Comment: Study identifies genetic variant that signifies higher risk for...
Dr Wendy Stock - University of Chicago, Chicago, USA
Comment: Study identifies genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia ( Dr Wendy Stock - University of Chicago, Chicago, USA )
5 Dec 2015
Comment: Genetic variants for increased risk of osteonecrosis in paediatric...
Dr Wendy Stock - University of Chicago, Chicago, USA
Comment: Genetic variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified ( Dr Wendy Stock - University of Chicago, Chicago, USA )
5 Dec 2015
Engineered cells to target multiple myeloma
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
Engineered cells to target multiple myeloma ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
5 Dec 2015
Whole exome sequencing finds genes associated with autoimmune platelet disorder...
Dr Jenny M. Despotovic - Texas Children’s Cancer and Hematology Centers...
Whole exome sequencing finds genes associated with autoimmune platelet disorder in children ( Dr Jenny M. Despotovic - Texas Children’s Cancer and Hematology Centers, Houston, USA )
5 Dec 2015
Classification system based on cytogenetics and treatment response identifies...
Dr Elizabeth Raetz - University of Utah, Salt Lake City, USA
Classification system based on cytogenetics and treatment response identifies leukaemia patients with high risk clinical features with outstanding outcomes ( Dr Elizabeth Raetz - University of Utah, Salt Lake City, USA )
5 Dec 2015
Study identifies genetic variant that signifies higher risk for avascular...
Dr Peter D. Cole - Albert Einstein College of Medicine, New York, USA
Study identifies genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia ( Dr Peter D. Cole - Albert Einstein College of Medicine, New York, USA )
5 Dec 2015
Genetic variants for increased risk of osteonecrosis in paediatric acute...
Dr Seth Karol - St Jude Children's Research Hospital, Tampa, USA
Genetic variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified ( Dr Seth Karol - St Jude Children's Research Hospital, Tampa, USA )
5 Dec 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation